Several high-profile startups that promised to draw insights from the bacteria living in and on us, known as the microbiome, have failed in recent months. One of them, a company called uBiome that was valued at $600 million, said it would shut down on Oct. 1 after months of challenges and setbacks. Yet investors still see the microbiome as a lucrative opportunity for the burgeoning digital health industry, which has raked in $36.3 billion from investors since 2011. Here's how the microbiome companies they're betting on plan to succeed. Click here for more BI Prime stories.